A novel anti-ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 6, 2007, Pages 1195-1200

  Zafar, M U ^a   Vilahur, G ^b   Choi, B G ^a   Ibanez, B ^a   Viles Gonzalez, J F ^a   Salas, E ^a   Badimon, Juan J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CSIC   (Spain)

Author keywords

Antiplatelet agents; Nitric oxide; Thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR; LA 419; NITRIC OXIDE DONOR; UNCLASSIFIED DRUG;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; HYPOTENSION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE MEMBRANE; THROMBOGENESIS; THROMBOSIS;

ADULT; ANTIBODIES, MONOCLONAL; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; ISOSORBIDE DINITRATE; MALE; NITRIC OXIDE DONORS; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION INHIBITORS; RECEPTORS, FIBRINOGEN; THROMBOSIS;

EID: 34250170509     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02543.x     Document Type: Article

References (38)

1. Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 2000; 101: 2144-8.
2. Bath PM, Hassall DG, Gladwin AM, Palmer RM, Martin JF. Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb 1991; 11: 254-60.
3. McNamara DB, Bedi B, Aurora H, Tena L, Ignarro LJ, Kadowitz PJ, Akers DL. L-arginine inhibits balloon catheter-induced intimal hyperplasia. Biochem Biophys Res Commun 1993; 193: 291-6.
4. Rubbo H, Parthasarathy S, Barnes S, Kirk M, Kalyanaraman B, Freeman BA. Nitric oxide inhibition of lipoxygenase-dependent liposome and low-density lipoprotein oxidation: Termination of radical chain propagation reactions and formation of nitrogen-containing oxidized lipid derivatives. Arch Biochem Biophys 1995; 324: 15-25.
5. Radomski MW, Palmer RM, Moncada S. The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-46.
6. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997-1000.
7. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057-8.
8. Niu XF, Ibbotson G, Kubes P. A balance between nitric oxide and oxidants regulates mast cell-dependent neutrophil-endothelial cell interactions. Circ Res 1996; 79: 992-9.
9. Freedman JE, Ting B, Hankin B, Loscalzo J, Keaney JF Jr, Vita JA. Impaired platelet production of nitric oxide predicts presence of acute coronary syndromes. Circulation 1998; 98: 1481-6.
10. Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Luscher TF. Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis. Circulation 1998; 97: 2494-8.
11. Harrison DG, Ohara Y. Physiologic consequences of increased vascular oxidant stresses in hypercholesterolemia and atherosclerosis: implications for impaired vasomotion. Am J Cardiol 1995; 75: 75B-81B.
12. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-8.
13. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86.
14. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 1227-34.
15. Repolles Moliner J, Pubill Coy F, Cabeza LL, Carbo BML, Negrie Rofes C, Cerda Riudavets JA, Ferrer Siso A, Radomski MW, Salas Perez-Rasilla E, Martinez Bonnin J. Derivatives of isosorbid mononitrate as vasodilator agents with reduced tolerance. International patent number WO0020420.
16. Vilahur G, Segales E, Casani L, Badimon L. A novel anti-ischemic nitric oxide donor inhibits thrombosis without modifying haemodynamic parameters. Thromb Haemost 2004; 91: 1035-43.
17. Vilahur G, Casani L, Salas E, Badimon L. Synergystic antithrombotic effect of LA419 and clopidogrel. Atherosclerosis 2004; 5: 100.
18. Hernandez MR, Tonda R, Arderiu G, Pino M, Serradell M, Escolar G. Antithrombotic effect of a new nitric oxide donor (LA419) on experimental thrombogenesis. Eur J Clin Invest 2005; 35: 337-42.
19. Badimon JJ, Lettino M, Toschi V, Fuster V, Berrozpe M, Chesebro JH, Badimon L. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-7.
20. Badimon JJ, Meyer B, Feigen LP, Baron DA, Chesebro JH, Fuster V, Badimon L. Thrombosis triggered by severe arterial lesions is inhibited by oral administration of a glycoprotein IIb/IIIa antagonist. Eur J Clin Invest 1997; 27: 568-74.
21. Badimon L, Badimon JJ. Mechanisms of arterial thrombosis in nonparallel streamlines: Platelet thrombi grow on the apex of stenotic severely injured vessel wall. Experimental study in the pig model. J Clin Invest 1989; 84: 1134-44.
22. Baumgartner HR. The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res 1973; 5: 167-79.
23. Varon D, Dardik R, Shenkman B, Kotev-Emeth S, Farzame N, Tamarin I, Savion N. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions. Thromb Res 1997; 85: 283-94.
24. Osende JI, Fuster V, Lev EI, Shimbo D, Rauch U, Marmur JD, Richard M, Varon D, Badimon JJ. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: Relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 2001; 103: 1488-91.
25. Corti R, Farkouh ME, Badimon JJ. The vulnerable plaque and acute coronary syndromes. Am J Med 2002; 113: 668-80.
26. Bhatt DL, Topol EJ. Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. JAMA 2000; 284: 1549-58.
27. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336: 1689-96.
28. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.
29. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997; 349: 1429-35.
30. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-61.
31. Marciniak SJ Jr, Mascelli MA, Furman MI, Michelson AD, Jakubowski JA, Jordan RE, Marchese PJ, Frelinger AL. An additional mechanism of action of abciximab: Dispersal of newly formed platelet aggregates. Thromb Haemost 2002; 87: 1020-5.
32. Pyatakova NV, Khropov YV, Churakov AM, Tarasova NI, Serezhenkov VA, Vanin AF, Tartakovsky VA, Severina IS. Derivatives of benzotetrazine-1,3-dioxide are new NO-donors, activators of soluble guanylate cyclase, and inhibitors of platelet aggregation. Biochemistry (Mosc) 2002; 67: 329-34.
33. Tanner FC, Meier P, Greutert H, Champion C, Nabel EG, Luscher TF. Nitric oxide modulates expression of cell cycle regulatory proteins: A cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. Circulation 2000; 101: 1982-9.
34. Groves PH, Banning AP, Penny WJ, Newby AC, Cheadle HA, Lewis MJ. The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty. Cardiovasc Res 1995; 30: 87-96.
35. Newby AC, Southgate KM, Assender JW. Inhibition of vascular smooth muscle cell proliferation by endothelium-dependent vasodilators. Herz 1992; 17: 291-9.
36. Bundy RE, Marczin N, Birks EF, Chester AH, Yacoub MH. Transplant atherosclerosis: Role of phenotypic modulation of vascular smooth muscle by nitric oxide. Gen Pharmacol 2000; 34: 73-84.
37. Yao SK, Akhtar S, Scott-Burden T, Ober JC, Golino P, Buja LM, Casscells W, Willerson JT. Endogenous and exogenous nitric oxide protect against intracoronary thrombosis and reocclusion after thrombolysis. Circulation 1995; 92: 1005-10.
38. Bednar MM, Gross CE, Howard DB, Russell SR, Thomas GR. Nitric oxide reverses aspirin antagonism of t-PA thrombolysis in a rabbit model of thromboembolic stroke. Exp Neurol 1997; 146: 513-7.